Adding 177Lu-PSMA-617 to combination therapy improves disease control in PSMA+ mHSPC while maintaining quality of life and ...
The consensus marks a sequential improvement from the third quarter, when Amneal earned $0.17 per share on revenue of $785 million. Investors will scrutinize whether the Bridgewater, N.J.-based ...
The Women’s Health Initiative study in 2002 had a lasting negative effect on the use of menopausal hormone therapy (MHT), which combines estrogen with medroxyprogesterone acetate (MPA). Although the ...
Biosimilar Ranluspec is used to treat neovascular (wet) age-related macular degeneration and other retinal vascular disorders ...
Budget impact analysis finds omalizumab biosimilars in Europe could cut payer costs by €641M in 5 years, expanding access and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results